Selected research
Industry Research
Recombinant Follicle Stimulating Hormone Industry Research Report 2026
Market perspective
The global Recombinant Follicle Stimulating Hormone market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Follicle Stimulating Hormone is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Follicle Stimulating Hormone is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Follicle Stimulating Hormone is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Follicle Stimulating Hormone include Teva, MSD, Merck Serono, Techwell, GenSci and Gedeon Richter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Follicle Stimulating Hormone market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Follicle Stimulating Hormone Market by Company
Teva
MSD
Merck Serono
Techwell
GenSci
Gedeon Richter
Recombinant Follicle Stimulating Hormone Segment by Type
75IU
150IU
Others
Recombinant Follicle Stimulating Hormone Segment by Application
Infertility Treatment
Assisted Reproductive Technology
Recombinant Follicle Stimulating Hormone Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Follicle Stimulating Hormone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Follicle Stimulating Hormone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Follicle Stimulating Hormone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Follicle Stimulating Hormone manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Follicle Stimulating Hormone by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Follicle Stimulating Hormone in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 75IU
- 150IU
- Others
Applications
- Infertility Treatment
- Assisted Reproductive Technology
Companies covered
- Teva
- MSD
- Merck Serono
- Techwell
- GenSci
- Gedeon Richter
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Follicle Stimulating Hormone Market Size (2021-2032)
- 2.2.2 Global Recombinant Follicle Stimulating Hormone Sales (2021-2032)
- 2.2.3 Global Recombinant Follicle Stimulating Hormone Market Average Price (2021-2032)
- 2.3 Recombinant Follicle Stimulating Hormone by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 75IU
- 2.3.3 150IU
- 2.3.4 Others
- 2.4 Recombinant Follicle Stimulating Hormone by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infertility Treatment
- 2.4.3 Assisted Reproductive Technology
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Follicle Stimulating Hormone Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Follicle Stimulating Hormone Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Follicle Stimulating Hormone Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Follicle Stimulating Hormone Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Follicle Stimulating Hormone Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Follicle Stimulating Hormone, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Follicle Stimulating Hormone, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Follicle Stimulating Hormone, Established Date
- 3.9 Global Recombinant Follicle Stimulating Hormone Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 MSD
- 4.2.1 MSD Company Information
- 4.2.2 MSD Business Overview
- 4.2.3 MSD Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 MSD Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.2.5 MSD Recent Developments
- 4.3 Merck Serono
- 4.3.1 Merck Serono Company Information
- 4.3.2 Merck Serono Business Overview
- 4.3.3 Merck Serono Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Serono Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.3.5 Merck Serono Recent Developments
- 4.4 Techwell
- 4.4.1 Techwell Company Information
- 4.4.2 Techwell Business Overview
- 4.4.3 Techwell Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Techwell Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.4.5 Techwell Recent Developments
- 4.5 GenSci
- 4.5.1 GenSci Company Information
- 4.5.2 GenSci Business Overview
- 4.5.3 GenSci Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GenSci Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.5.5 GenSci Recent Developments
- 4.6 Gedeon Richter
- 4.6.1 Gedeon Richter Company Information
- 4.6.2 Gedeon Richter Business Overview
- 4.6.3 Gedeon Richter Recombinant Follicle Stimulating Hormone Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Gedeon Richter Recombinant Follicle Stimulating Hormone Product Portfolio
- 4.6.5 Gedeon Richter Recent Developments
5 Global Recombinant Follicle Stimulating Hormone Market Scenario by Region
- 5.1 Global Recombinant Follicle Stimulating Hormone Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Follicle Stimulating Hormone Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Follicle Stimulating Hormone Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Follicle Stimulating Hormone Sales by Region: 2027-2032
- 5.3 Global Recombinant Follicle Stimulating Hormone Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Follicle Stimulating Hormone Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Follicle Stimulating Hormone Revenue by Region: 2027-2032
- 5.4 North America Recombinant Follicle Stimulating Hormone Market Facts & Figures by Country
- 5.4.1 North America Recombinant Follicle Stimulating Hormone Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Follicle Stimulating Hormone Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Follicle Stimulating Hormone Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Recombinant Follicle Stimulating Hormone Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Follicle Stimulating Hormone Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Follicle Stimulating Hormone Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Follicle Stimulating Hormone Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Recombinant Follicle Stimulating Hormone Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Follicle Stimulating Hormone Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Follicle Stimulating Hormone Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Follicle Stimulating Hormone Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Follicle Stimulating Hormone Market Facts & Figures by Country
- 5.7.1 South America Recombinant Follicle Stimulating Hormone Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Follicle Stimulating Hormone Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Follicle Stimulating Hormone Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Recombinant Follicle Stimulating Hormone Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Follicle Stimulating Hormone Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Follicle Stimulating Hormone Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Follicle Stimulating Hormone Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Recombinant Follicle Stimulating Hormone Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Follicle Stimulating Hormone Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Recombinant Follicle Stimulating Hormone Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Follicle Stimulating Hormone Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Follicle Stimulating Hormone Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Follicle Stimulating Hormone Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Follicle Stimulating Hormone Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Follicle Stimulating Hormone Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Follicle Stimulating Hormone Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Recombinant Follicle Stimulating Hormone Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Follicle Stimulating Hormone Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Follicle Stimulating Hormone Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Follicle Stimulating Hormone Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Follicle Stimulating Hormone Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Follicle Stimulating Hormone Value Chain Analysis
- 8.1.1 Recombinant Follicle Stimulating Hormone Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Follicle Stimulating Hormone Production Mode & Process
- 8.2 Recombinant Follicle Stimulating Hormone Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Follicle Stimulating Hormone Distributors
- 8.2.3 Recombinant Follicle Stimulating Hormone Customers
9 Global Recombinant Follicle Stimulating Hormone Analyzing Market Dynamics
- 9.1 Recombinant Follicle Stimulating Hormone Industry Trends
- 9.2 Recombinant Follicle Stimulating Hormone Industry Drivers
- 9.3 Recombinant Follicle Stimulating Hormone Industry Opportunities and Challenges
- 9.4 Recombinant Follicle Stimulating Hormone Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst